3 result(s) displayed (1 - 3 of 3):

Pharma's flurry of small deals as 2008 winds down (from Corporate Dealmaker)

M&A in the drug world might be stalled, with Example No. 1 being Roche Holding AG's $44 billion bid for Genentech Inc., but the year is ending with a burst of licensing activity.   The week before Christmas, we reported in The Deal (subscription required) at least six deals that...

Posted on December 31, 2008 8:55 AM

Roche-Genentech: Compensation and culture clash (from Corporate Dealmaker)

"We're very conscious of the remuneration culture that exists in that part of the world," Roche Holding AG chairman Franz Humer said. "We need to be competitive with regard to the companies around Genentech. We're willing to embark on various alternatives."Humer, speaking in New York on Tuesday about the bid...

Posted on July 23, 2008 10:05 AM

Maybe Roche's plan allows for Genentech culture clash (from Corporate Dealmaker)

Writing in The Deal (subscription required), Alex Lash called Roche Holding AG's move to buy out the 44% of Genentech Inc. that it doesn't own "shocking." One of those shocked, apparently, was Genentech CEO Art Levinson. And if you buy the analysis of Roger Longman over on the In Vivo...

Posted on July 22, 2008 9:09 AM